Currently out of the existing stock ratings of Jeffrey Hung, 131 are a HOLD (36.49%), 19 are a SELL (5.29%), 209 are a BUY (58.22%).

Jeffrey Hung

Work Performance Price Targets & Ratings Chart

Analyst Jeffrey Hung, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 62.84% that have a potential upside of 33.35% achieved within 179 days.

Jeffrey Hung’s has documented 696 price targets and ratings displayed on 47 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CTNM, Contineum Therapeutics at 28-Sep-2026.

Wall Street Analyst Jeffrey Hung

Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) at 11/9/2022. The price target of $26 was fulfilled within 2 days with a profit of $3.75 (16.85%) receiving and performance score of 84.27.

Average potential price target upside

of $295.17 (34.7%) on BLUE (BLUEBIRD BIO).
of $63 (39.53%) on NXTC (NEXTCURE).
of $61.16 (30.86%) on KRTX (KARUNA THERAPEUTICS).

ACAD ACADIA Pharmaceuticals CYTK Cytokinetics ESPR Esperion Therapeutics EVFM Evofem Biosciences EXEL Exelixis PRLD Prelude Therapeutics RARE Ultragenyx VYGR Voyager Therapeutics APRE Aprea Therapeutics BCYC Bicycle Therapeutics Ltd JAZZ Jazz Pharmaceuticals PLC MYOK MyoKardia NBIX Neurocrine Biosciences NXTC NextCure RPTX Repare Therapeutics CELU Celularity CGEM Cullinan Oncology LLC CINC CinCor Pharma GRPH Graphite Bio RUBY Rubius Therapeutics CYT Cyteir Therapeutics RYTM Rhythm Pharmaceuticals XLRN Acceleron Pharma ERAS Erasca IMRX Immuneering Corp ITCI Intracellular Th KRTX Karuna Therapeutics PTCT PTC Therapeutics CRNX Crinetics Pharmaceuticals FOLD Amicus Therapeutics INSM Insmed ENGN enGene Holdings IRON Disc Medicine AKBA Akebia Ther ALDR Alder BioPharmaceuticals CNCE Concert Pharmaceuticals CNTA Centessa Pharmaceuticals PLC ADR PRVL Prevail Therapeutics BIOA BioAge Labs SELB Selecta Biosciences IMCR Immunocore Holdings Ltd BHVN Biohaven Pharmaceutical Holding Co Ltd BLUE Bluebird bio CGON CG Oncology CTNM Contineum Therapeutics RPT RPT Realty VIGL Vigil Neuroscience

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ami Fadia (NEEDHAM)

Buy Since 27-Feb-2024

$35

$15.2 (76.77%)

$35

Please subscribe to see extended stock data

Brian Abrahams (RBC)

Buy Since 22-Jun-2025

$36

$16.2 (81.82%)

$37

12 days ago
(07-Oct-2026)

1/10 (10%)

$16.42 (83.86%)

173

Please subscribe to see extended stock data

Ananda Ghosh (HC WAINWRIGHT)

Buy Since 14-Dec-2025

$33

$13.2 (66.67%)

$37

25 days ago
(24-Sep-2026)

0/3 (0%)

$12.32 (59.57%)

Please subscribe to see extended stock data

Evan Seigerman (BMO)

Buy Since 16-Apr-2025

$34

$14.2 (71.72%)

$36

25 days ago
(24-Sep-2026)

4/6 (66.67%)

$13.32 (64.41%)

144

Please subscribe to see extended stock data

David Hoang (DEUTSCHE BANK)

Buy Since 24-Sep-2025

$31

$11.2 (56.57%)

$38

25 days ago
(24-Sep-2026)

1/4 (25%)

$10.32 (49.90%)

831

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Jeffrey Hung most bullish on?

Potential upside of $111.77 has been obtained for JAZZ (JAZZ PHARMACEUTICALS PLC)

Which stock is Jeffrey Hung most reserved on?

Potential downside of $8.2 has been obtained for ACAD (ACADIA PHARMACEUTICALS)

What Year was the first public recommendation made by Jeffrey Hung?

On 2015